⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31348874 | 1.00 | NSD2 (0.63) | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL61082 | 1.00 | — | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL21462059 | 1.00 | NSD2 (0.63) | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL27906548 | 0.97 | — | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL20515161 | 0.97 | NSD2 (0.60) | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL1320265 | 0.97 | — | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL8881137 | 0.97 | NSD2 (0.60) | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL8881129 | 0.97 | — | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL5960762 | 0.94 | — | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL2375807 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545580-A4 | NEW THERAPEUTIC USES OF TRI-, TETRA-, PENTA-, AND POLYPEPTIDES | INNAPHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080176806-A1 | Therapeutic uses of tri-, tetra-, penta-, and polypeptides | INNAPHARMA, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080004224-A1 | DERMATOLOGICAL USES OF TRI-, TETRA-, PENTA-, AND POLYPEPTIDES | HLAVKA JOSEPH J | 2008-01-03 | — | — | US | disclosed |
| WO-2007137015-A2 | DERMATOLOGICAL USES OF TRI-, TETRA-, PENTA-, AND POLYPEPTIDES | TETRAGENEX PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1545580-A2 | NEW THERAPEUTIC USES OF TRI-, TETRA-, PENTA-, AND POLYPEPTIDES | Innapharma, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6767897-B2 | ADMINISTERING TO THE PATIENT AT LEAST ONE TETRAPEPTIDE OR SALT THEREOF FOR THERAPY OF PHYSIOLOGICAL, PSYCHOSOMATIC, NEUROLOGICAL OR PSYCHIATRIC DISORDER | INNAPHARMA, INC. | 2004-07-27 | — | — | US | disclosed |
| WO-2003087137-A2 | NEW THERAPEUTIC USES OF TRI-, TETRA-, PENTA-, AND POLYPEPTIDES | INNAPHARMA, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030176354-A1 | Therapeutic uses of tri-, tetra-, penta-, and polypeptides | TETRAGENEX PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6093797-A | MODIFICATIONS OF THE TRIPEPTIDE HORMONE MELANOCYTE STIMULATING INHIBITORY FACTOR; CAN CROSS BLOOD-BRAIN BARRIER; SIDE EFFECT REDUCTION | INNAPHARMA, INC. (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999022758-A1 | TRI-, TETRA-, PENTA-, AND POLYPEPTIDES AND THEIR THERAPEUTIC USE AS AN ANTIDEPRESSANT AGENT | INNAPHARMA, INC. (US) | 1999-05-14 | — | — | WO | disclosed |